Orgaran (Danaparoid Sodium)

Orgaran is a heparinoid anticoagulant that acts on the coagulation cascade to reduce clot formation.

• Deep vein thrombosis: prevents clot propagation and facilitates resolution in at‑risk patients.
• Pulmonary embolism: reduces the size of existing emboli and prevents new clot formation in the pulmonary arteries.
• Heparin‑induced thrombocytopenia (HIT): provides an alternative anticoagulant option when heparin therapy is contraindicated.

• Danaparoid Sodium exerts its antithrombotic effect by indirectly inhibiting factor Xa. It enhances the activity of antithrombin III and heparin cofactor II, leading to reduced conversion of prothrombin to thrombin and consequently decreasing fibrin clot formation.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Minor bleeding at injection site: mild bruising or oozing.
• Gastrointestinal upset: nausea or abdominal discomfort.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Rash or mild skin irritation: localized erythema.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening internal bleeding.
• Thrombocytopenia: significant drop in platelet count unrelated to HIT.
• Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention.

Use Orgaran only under careful clinical supervision and after evaluating individual risk factors.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Bleeding risk: assess patient history of bleeding disorders before initiation.
• History of HIT: contraindicated in patients with prior heparin‑induced thrombocytopenia.
• Concurrent anticoagulants: avoid combination with other anticoagulant agents unless specifically directed.
• Pregnancy: consider only if potential benefits outweigh risks to the fetus.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Co‑administration with certain drugs can alter anticoagulant effect.

Major Interactions (Avoid)

• Direct thrombin inhibitors (e.g., dabigatran): may cause uncontrolled bleeding.
• High‑dose aspirin or other antiplatelet agents: significantly increase hemorrhagic risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may potentiate bleeding tendency.
• Certain antibiotics (e.g., quinolones): can affect platelet function.
• Vitamin K antagonists (e.g., warfarin): may require dose adjustments and close INR monitoring.